Piramal Pharma's Q2 FY 2025-26 Quarterly Results

Result Summary

• Piramal Pharma Ltd reported a 5.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 8.4%.
• Its expenses for the quarter were up by 2.8% QoQ and down 1.4% YoY.
• The net profit increased 21.4% QoQ and decreased 539.2% YoY.
• The earnings per share (EPS) of Piramal Pharma Ltd declined at 0.75 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Piramal Pharma Ltd is a significant entity within the pharmaceutical industry, offering a range of products and services. The company is known for its contributions to healthcare and pharmaceuticals, including drug discovery, development, and manufacturing. It operates in a competitive industry characterized by constant innovation and regulatory challenges. Recent developments within the company or industry are not available from the provided data, and thus, any specific advancements or changes are not detailed in this report.

Revenue

During Q2FY26, Piramal Pharma Ltd reported a total income of ₹2109.32 crores, marking a 5.9% increase from the previous quarter's income of ₹1992.11 crores. However, when compared to the same quarter of the previous fiscal year (Q2FY25), which recorded a total income of ₹2302.86 crores, there was an 8.4% decline in revenue. This year-over-year decrease highlights changes in revenue generation over the period. The quarterly increase suggests a positive movement from the immediate past quarter, although a comparison with the previous year's data indicates a broader contraction in revenue.

Profitability

The company's profitability metrics reflect a challenging period. In Q2FY26, Piramal Pharma Ltd reported a profit before tax of -₹60.97 crores, which, while still negative, represents a 37.5% improvement from the previous quarter's -₹97.59 crores. Compared to the profit before tax of ₹102.86 crores in Q2FY25, there is a significant year-over-year drop of 159.3%. Tax expenses have increased dramatically quarter-over-quarter by 1879.1% to ₹53.04 crores, although they are lower compared to ₹97.53 crores in the same quarter last year, a 45.6% decrease year-over-year. The profit after tax for Q2FY26 stands at -₹99.22 crores, a deterioration from the -₹81.70 crores reported in Q1FY26 and a stark contrast to the positive ₹22.59 crores in Q2FY25, reflecting a year-over-year decline of 539.2%. The earnings per share (EPS) also followed a similar trend with a value of -₹0.75 in Q2FY26, compared to -₹0.62 in Q1FY26 and ₹0.17 in Q2FY25, reflecting a year-over-year decrease of 541.2%.

Operating Metrics

In terms of operating metrics, total expenses for Q2FY26 were ₹2170.29 crores, showing a 2.8% increase from ₹2110.44 crores in Q1FY26. When compared with Q2FY25, where expenses were ₹2200.00 crores, there was a slight decrease of 1.4%. This indicates changes in the company's cost structure and operational efficiency between the periods. The financial data does not provide specific details on other operating ratios such as P/E ratio, debt-to-equity ratio, or current ratio, and thus these specific metrics are not included in this analysis. However, the available data highlights the trends in income and expenses, essential for understanding the company's operational dynamics.